Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Menactra in South Korea
NCT01642589Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2012
- Primary completion
- Jan 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of meningococcal A conjugate vaccine in meningococcal disease (2 arms), sponsored by Sanofi. Primary endpoint: Percentage of Participants With Seroconversion at 28 days. Started Jul 2012; status: completed.
02
Drugs
meningococcal A conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT01642589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01642589.